Gavin Y Oudit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6776368/publications.pdf

Version: 2024-02-01

304 papers	23,274 citations	7096 78 h-index	9589 142 g-index
305 all docs	305 docs citations	305 times ranked	26999 citing authors

#	Article	IF	Citations
1	Burden of Valvular Heart Disease in Patients with Fabry Disease. Journal of the American Society of Echocardiography, 2022, 35, 236-238.	2.8	3
2	Cardiac Complications of Common Drugs of Abuse: Pharmacology, Toxicology, and Management. Canadian Journal of Cardiology, 2022, 38, 1331-1341.	1.7	8
3	Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists. Peptides, 2022, 147, 170697.	2.4	18
4	Sex- and age-specific regulation of ACE2: Insights into severe COVID-19 susceptibility. Journal of Molecular and Cellular Cardiology, 2022, 164, 13-16.	1.9	28
5	Dysregulation of ACE (Angiotensin-Converting Enzyme)-2 and Renin-Angiotensin Peptides in SARS-CoV-2 Mediated Mortality and End-Organ Injuries. Hypertension, 2022, 79, 365-378.	2.7	50
6	Unraveling the Genetic Substrate and Phenotypic Variability of Hypertrophic Cardiomyopathy: A Role for Desmosome Gene Variants?. Canadian Journal of Cardiology, 2022, 38, 3-5.	1.7	3
7	ADAM15 is required for optimal collagen cross-linking and scar formation following myocardial infarction. Matrix Biology, 2022, 105, 127-143.	3.6	9
8	Critical Role of Extracellular Matrix Remodelling in Patients With Dilated Cardiomyopathy: Lessons From Connective Tissue Disorders. Canadian Journal of Cardiology, 2022, 38, 309-310.	1.7	2
9	Transcriptomic Signatures of End-Stage Human Dilated Cardiomyopathy Hearts with and without Left Ventricular Assist Device Support. International Journal of Molecular Sciences, 2022, 23, 2050.	4.1	4
10	RPIâ€194 is a Novel Troponin Activator that Increases the Calcium Sensitivity of Striated Muscle Contraction. FASEB Journal, 2022, 36, .	0.5	0
11	Demystifying Cardiac Iron Deficiency in Endâ€stage Heart Failure. FASEB Journal, 2022, 36, .	0.5	0
12	An advanced endothelial murine HFpEF model: eNOS is critical for angiotensin 1â€“7 rescue of the diabetic phenotype. Journal of Molecular and Cellular Cardiology, 2022, 169, 10-12.	1.9	0
13	Changes in the Left Ventricular Eicosanoid Profile in Human Dilated Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	3
14	Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. Journal of the American Heart Association, 2022, 11, .	3.7	22
15	Low Prevalence of Cardiomyopathy in Patients with Mitochondrial Disease and Neurological Manifestations. Journal of Cardiovascular Development and Disease, 2022, 9, 221.	1.6	1
16	Structural Valve Deterioration Is Linked to Increased Immune Infiltrate and Chemokine Expression. Journal of Cardiovascular Translational Research, 2021, 14, 503-512.	2.4	11
17	Evaluating the diagnostic and prognostic value of biomarkers for heart disease and major adverse cardiac events in patients with muscular dystrophy. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 564-573.	4.0	8
18	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. European Heart Journal Cardiovascular Imaging, 2021, 22, 220-228.	1.2	10

#	Article	IF	Citations
19	The Human Explanted Heart Program: A translational bridge for cardiovascular medicine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165995.	3.8	14
20	Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H296-H304.	3.2	123
21	The tumor microenvironment may trigger lymphoproliferation in cardiac myxoma. Translational Oncology, 2021, 14, 100911.	3.7	10
22	Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators. RSC Medicinal Chemistry, 2021, 12, 1402-1413.	3.9	6
23	Soluble Epoxide Hydrolase in Aged Female Mice and Human Explanted Hearts Following Ischemic Injury. International Journal of Molecular Sciences, 2021, 22, 1691.	4.1	12
24	Sickle cell disease, interleukin-18, and arrhythmias. Blood, 2021, 137, 1138-1139.	1.4	1
25	Cardiomyopathies and Genetic Testing in Heart Failure: Role in Defining Phenotype-Targeted Approaches and Management. Canadian Journal of Cardiology, 2021, 37, 547-559.	1.7	23
26	Effect of Active Cancer on the Cardiac Phenotype: A Cardiac Magnetic Resonance Imagingâ€Based Study of Myocardial Tissue Health and Deformation in Patients With Chemotherapyâ€NaÃ¯ve Cancer. Journal of the American Heart Association, 2021, 10, e019811.	3.7	19
27	Cardiac reverse remodelling and health status in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 3106-3118.	3.1	10
28	Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H2255-H2269.	3.2	9
29	Loss of TIMP4 (Tissue Inhibitor of Metalloproteinase 4) Promotes Atherosclerotic Plaque Deposition in the Abdominal Aorta Despite Suppressed Plasma Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1874-1889.	2.4	10
30	Clinical utility of 12â€lead electrocardiogram in evaluating heart disease in patients with muscular dystrophy: Assessment of left ventricular hypertrophy, conduction disease, and cardiomyopathy. Annals of Noninvasive Electrocardiology, 2021, 26, e12876.	1.1	4
31	Looking at the Right Side: Amenability of the Right Ventricle to Therapy in Patients With Titin-Related Dilated Cardiomyopathy. Canadian Journal of Cardiology, 2021, 37, 1699-1701.	1.7	0
32	Pharmacological and cell-specific genetic PI3KÎ± inhibition worsens cardiac remodeling after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2021, 157, 17-30.	1.9	9
33	Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 5352-5362.	3.1	12
34	Gelsolin is an important mediator of Angiotensin IIâ€induced activation of cardiac fibroblasts and fibrosis. FASEB Journal, 2021, 35, e21932.	0.5	8
35	Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform. International Journal of Molecular Sciences, 2021, 22, 12617.	4.1	3
36	Abstract 11800: Inhibition of Pyruvate Dehydrogenase Kinase Does Not Improve Cardiac Abnormalities in a Mouse Model of Human Barth Syndrome. Circulation, 2021, 144, .	1.6	1

#	Article	IF	Citations
37	Battle of the Sexes: Differential Prognosis by Sex in Dilated Cardiomyopathy. Canadian Journal of Cardiology, 2020, 36, 7-10.	1.7	5
38	Cardiogenic Shock With Takotsubo Syndrome vs Myocardial Infarction: Better Short-term Outcomes but Significant Long-term Risk and Need for Surveillance. Canadian Journal of Cardiology, 2020, 36, 802-804.	1.7	1
39	Optimizing PEG-Extended Apelin Analogues as Cardioprotective Drug Leads: Importance of the KFRR Motif and Aromatic Head Group for Improved Physiological Activity. Journal of Medicinal Chemistry, 2020, 63, 12073-12082.	6.4	14
40	SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes. Diabetes, 2020, 69, 1875-1886.	0.6	61
41	Cells of the adult human heart. Nature, 2020, 588, 466-472.	27.8	852
42	Bioinformatic analysis of membrane and associated proteins in murine cardiomyocytes and human myocardium. Scientific Data, 2020, 7, 425.	5.3	8
43	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 81.	3.3	21
44	COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada. CJC Open, 2020, 2, 265-272.	1.5	12
45	Inactivation of endothelial cell phosphoinositide 3-kinase Î² inhibits tumor angiogenesis and tumor growth. Oncogene, 2020, 39, 6480-6492.	5.9	11
46	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases. Hypertension, 2020, 76, 651-661.	2.7	57
47	Change of Healthâ€Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure. Journal of the American Heart Association, 2020, 9, e017278.	3.7	23
48	Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19. European Heart Journal, 2020, 41, 1818-1820.	2.2	65
49	SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2020, 319, E43-E47.	3.5	24
50	ADAM (a Disintegrin and Metalloproteinase) 15 Deficiency Exacerbates Ang II (Angiotensin II)â€“Induced Aortic Remodeling Leading to Abdominal Aortic Aneurysm. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1918-1934.	2.4	31
51	ACE2 (Angiotensin-Converting Enzyme 2)-Mediated Protection From Pulmonary Hypertension. Hypertension, 2020, 76, 28-29.	2.7	4
52	Angiotensin Converting Enzyme 2. Circulation, 2020, 142, 426-428.	1.6	220
53	Use of Serial High-Sensitive Troponin T in Patients With Adult Congenital Heart Disease: Enhancing the Detection of Major Adverse Cardiac Events. Canadian Journal of Cardiology, 2020, 36, 1338-1340.	1.7	0
54	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. ESC Heart Failure, 2020, 7, 2725-2733.	3.1	7

#	Article	IF	Citations
55	Response by Gheblawi et al to Letter Regarding Article, â€œAngiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2â€. Circulation Research, 2020, 127, e46-e47.	4.5	16
56	Elevated Angiotensin 1â€“7/Angiotensin II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. Circulation: Heart Failure, 2020, 13, e006939.	3.9	28
57	Cardiac Intervention Improves Heart Disease and Clinical Outcomes in Patients With Muscular Dystrophy in a Multidisciplinary Care Setting. Journal of the American Heart Association, 2020, 9, e014004.	3.7	15
58	Stressâ€Induced Cyclin C Translocation Regulates Cardiac Mitochondrial Dynamics. Journal of the American Heart Association, 2020, 9, e014366.	3.7	10
59	Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. Circulation Research, 2020, 126, 1456-1474.	4.5	1,478
60	Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease. Clinical Science, 2020, 134, 827-851.	4.3	43
61	Cardiovascular toxicity of PI3KÎ± inhibitors. Clinical Science, 2020, 134, 2595-2622.	4.3	11
62	Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications. Clinical Science, 2020, 134, 2319-2336.	4.3	26
63	The dual nature of obesity in metabolic programming: quantity versus quality of adipose tissue. Clinical Science, 2020, 134, 2447-2451.	4.3	3
64	Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy. PLoS ONE, 2020, 15, e0239675.	2.5	14
65	Adipose biology, cardiovascular, and cardiometabolic disease: novel insights and new targets for intervention. Clinical Science, 2020, 134, 1473-1474.	4.3	1
66	Role of Epicardial Adipose Tissue in Heart Failure: From Basic to Clinical Perspectives. , 2020, , 173-194.		0
67	Sarcoidosis: a prospective observational cohort from Northern Alberta. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, e2020014.	0.2	0
68	Role of iron metabolism in heart failure: From iron deficiency to iron overload. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1925-1937.	3.8	94
69	Ventricular tachycardia in patients with type 1 myotonic dystrophy: a case series. European Heart Journal - Case Reports, 2019, 3, .	0.6	11
70	Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure. Cardiovascular Diabetology, 2019, 18, 86.	6.8	102
71	The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders. Annals of the New York Academy of Sciences, 2019, 1455, 12-33.	3.8	46
72	Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency. Circulation Research, 2019, 125, 969-988.	4.5	67

#	Article	IF	Citations
73	Screening and Initiating Supportive Care in Patients With Heart Failure. Frontiers in Cardiovascular Medicine, 2019, 6, 151.	2.4	5
74	ACE2 exerts anti-obesity effect via stimulating brown adipose tissue and induction of browning in white adipose tissue. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1140-E1149.	3.5	49
75	Quantification of lung water in heart failure using cardiovascular magnetic resonanceÂimaging. Journal of Cardiovascular Magnetic Resonance, 2019, 21, 58.	3.3	14
76	Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents. European Journal of Medicinal Chemistry, 2019, 166, 119-124.	5.5	35
77	Low altitude simulation without hypoxia improves left ventricular function after myocardial infarction by reducing ventricular afterload. PLoS ONE, 2019, 14, e0215814.	2.5	6
78	Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13006-13015.	7.1	39
79	Inhibition of PI3Kinase-Î± is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts. Journal of Molecular and Cellular Cardiology, 2019, 132, 98-109.	1.9	15
80	PI3KÎ± Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction. Journal of the American Heart Association, 2019, 8, e010961.	3.7	15
81	Weight loss enhances cardiac energy metabolism and function in heart failure associated with obesity. Diabetes, Obesity and Metabolism, 2019, 21, 1944-1955.	4.4	31
82	Cardiorenal Syndrome and Heart Failureâ€"Challenges and Opportunities. Canadian Journal of Cardiology, 2019, 35, 1208-1219.	1.7	40
83	The renin-angiotensin system: going beyond the classical paradigms. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H958-H970.	3.2	218
84	Testosterone and cardiac remodeling: why are older men susceptible to heart disease?. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H765-H767.	3.2	3
85	Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Type 1 Myotonic Dystrophy With Versus Without Left Bundle Branch Block. American Journal of Cardiology, 2019, 124, 1770-1774.	1.6	11
86	PI3KÎ± in cardioprotection: Cytoskeleton, late Na⁺ current, and mechanism of arrhythmias. Channels, 2019, 13, 520-532.	2.8	11
87	Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. Journal of Cardiovascular Pharmacology, 2019, 73, 149-154.	1.9	14
88	Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction. Cardiovascular Diabetology, 2019, 18, 1.	6.8	98
89	Endothelial and cardiomyocyte PI3KÎ²2 divergently regulate cardiac remodelling in response to ischaemic injury. Cardiovascular Research, 2019, 115, 1343-1356.	3.8	17
90	Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury. Journal of Clinical Investigation, 2019, 130, 94-107.	8.2	43

#	Article	IF	Citations
91	Investigating the role of endothelial cellâ€specific p110Î² isoform of PI3K as a potential target for antiâ€angiogenic therapy. FASEB Journal, 2019, 33, lb9.	0.5	0
92	Chloroquineâ€induced cardiomyopathy: a reversible cause of heart failure. ESC Heart Failure, 2018, 5, 372-375.	3.1	41
93	Advanced Dilated Cardiomyopathy in a Patient With Hutterite Limb-Girdle Muscular Dystrophy. Circulation: Heart Failure, 2018, 11, e004960.	3.9	8
94	Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in cardiovascular disease. Clinical Science, 2018, 132, 901-904.	4.3	22
95	Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice. Diabetes, 2018, 67, 1867-1879.	0.6	243
96	Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease. Canadian Journal of Cardiology, 2018, 34, 1041-1047.	1.7	19
97	A prospective evaluation of the established criteria for heart failure with preserved ejection fraction using the Alberta HEART cohort. ESC Heart Failure, 2018, 5, 19-26.	3.1	10
98	Angiotensin 1â€“7 stimulates brown adipose tissue and reduces diet-induced obesity. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E131-E138.	3.5	39
99	Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy. Bioscience Reports, 2018, 38, .	2.4	11
100	Effects of age, gender, and risk-factors for heart failure on native myocardial T1 and extracellular volume fraction using the SASHA sequence at 1.5T. Journal of Magnetic Resonance Imaging, 2018, 48, spcone-spcone.	3.4	0
101	PI3KÎ±-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease. Nature Communications, 2018, 9, 5390.	12.8	52
102	Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2018, 7, e009098.	3.7	52
103	Resistant Hypertension From Renal Artery Stenosis Leading to Heart Failure With Preserved Ejection Fraction. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961881650.	0.6	3
104	Caloric restriction limits fatty acid oxidation and improves cardiac function in heart failure associated with obesity. Journal of Molecular and Cellular Cardiology, 2018, 124, 99.	1.9	0
105	Breast Cancer Patients Receiving Anthracycline Chemotherapy and Trastuzumab Have Biventricular Dysfunction and Reduced Heart Mass. Journal of the American College of Cardiology, 2018, 72, 1872-1873.	2.8	7
106	Disparate Remodeling of the Extracellular Matrix and Proteoglycans in Failing Pediatric Versus Adult Hearts. Journal of the American Heart Association, 2018, 7, e010427.	3.7	27
107	Loss of Angiotensin-Converting Enzyme 2 Exacerbates Diabetic Retinopathy by Promoting Bone Marrow Dysfunction. Stem Cells, 2018, 36, 1430-1440.	3.2	43
108	Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm. Circulation Research, 2018, 123, 372-388.	4.5	51

#	Article	IF	Citations
109	TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H978-H990.	3.2	18
110	Empagliflozin Increases Cardiac EnergyÂProductionÂin Diabetes. JACC Basic To Translational Science, 2018, 3, 575-587.	4.1	263
111	Effects of age, gender, and riskâ€factors for heart failure on native myocardial T₁ and extracellular volume fraction using the SASHA sequence at 1.5T. Journal of Magnetic Resonance Imaging, 2018, 48, 1307-1317.	3.4	9
112	Alterations in the Eicosanoid Profile and Mitochondrial Injury in Human Ventricular Tissue Following Myocardial Infarction. FASEB Journal, 2018, 32, 561.6.	0.5	0
113	Recombinant Human ACE2 and the Angiotensin 1-7 Axis as Potential New Therapies for Heart Failure. Canadian Journal of Cardiology, 2017, 33, 943-946.	1.7	39
114	Females Are Protected From Ironâ€Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress. Journal of the American Heart Association, 2017, 6, .	3.7	29
115	Disrupting the key circadian regulator CLOCK leads to age-dependent cardiovascular disease. Journal of Molecular and Cellular Cardiology, 2017, 105, 24-37.	1.9	83
116	Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimentalÂAlport syndrome. Kidney International, 2017, 91, 1347-1361.	5.2	37
117	Novel Dominantâ€“Negative Mutation in Cardiac Troponin I Causes Severe Restrictive Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	9
118	Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 805-819.	2.8	160
119	Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy. Canadian Journal of Cardiology, 2017, 33, 883-897.	1.7	34
120	Reply. Journal of the American College of Cardiology, 2017, 69, 3011-3013.	2.8	0
121	Hemochromatosis Protein (HFE) Knockout Mice As a Novel Model of Hemochromatosis: Implications for Study and Management of Iron-Overload Cardiomyopathy. Canadian Journal of Cardiology, 2017, 33, 835-837.	1.7	6
122	Cardiac Med1 deletion promotes early lethality, cardiac remodeling, and transcriptional reprogramming. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H768-H780.	3.2	22
123	Tissue Inhibitor of Matrix Metalloproteinase-1 Promotes Myocardial Fibrosis by Mediating CD63â€“Integrin Î²1 Interaction. Hypertension, 2017, 69, 1092-1103.	2.7	108
124	Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101â€“Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal of Clinical Oncology, 2017, 35, 870-877.	1.6	292
125	GW28-e0806 Pyr1-Apelin 13 is a negative modulator of angiotensin II-mediated adverse myocardial hypertrophy, remodeling and fibrosis. Journal of the American College of Cardiology, 2017, 70, C29-C30.	2.8	0
126	Apelin Is a Negative Regulator of Angiotensin IIâ€“Mediated Adverse Myocardial Remodeling and Dysfunction. Hypertension, 2017, 70, 1165-1175.	2.7	85

#	Article	IF	Citations
127	Is Î²-Arrestin 2 a Magic Bullet for Heart Failure Treatment?. Hypertension, 2017, 70, 887-889.	2.7	7
128	Differentiating heart failure phenotypes using sexâ€specific transcriptomic and proteomic biomarker panels. ESC Heart Failure, 2017, 4, 301-311.	3.1	28
129	Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Failure Reviews, 2017, 22, 889-902.	3.9	156
130	Synthetic Modification within the â€œRPRLâ€•Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation. Journal of Medicinal Chemistry, 2017, 60, 6408-6427.	6.4	35
131	Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1942-1950.	3.8	81
132	Processes for Longitudinal Care of Sarcoidosis in Northern Alberta. Chest, 2017, 152, A454.	0.8	0
133	Ectopic expression of Cdk8 induces eccentric hypertrophy and heart failure. JCI Insight, 2017, 2, .	5.0	20
134	ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes, 2016, 65, 85-95.	0.6	193
135	Response to Comment on Patel et al. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes 2016;65:85â€“95. Diabetes, 2016, 65, e3-e4.	0.6	10
136	Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of ironâ€overload. Liver International, 2016, 36, 246-257.	3.9	38
137	Ces3/TGH Deficiency Attenuates Steatohepatitis. Scientific Reports, 2016, 6, 25747.	3.3	33
138	Reply to Letter From Floras etÂal.â€”Central Sleep Apnea: Risk Factor or Pathogenic Process in Patients With Heart Failure. Canadian Journal of Cardiology, 2016, 32, 396.e5.	1.7	0
139	Role of the ACE2/Angiotensin 1â€“7 Axis of the Reninâ€“Angiotensin System in Heart Failure. Circulation Research, 2016, 118, 1313-1326.	4.5	664
140	Angiotensin-converting enzyme 2 ameliorates renal fibrosis by blocking the activation of mTOR/ERK signaling in apolipoprotein E-deficient mice. Peptides, 2016, 79, 49-57.	2.4	36
141	Adeno-Associated Virus Overexpression of Angiotensin-Converting Enzyme-2 Reverses Diabetic Retinopathy in Type 1 Diabetes in Mice. American Journal of Pathology, 2016, 186, 1688-1700.	3.8	46
142	Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. European Heart Journal, 2016, 38, ehw386.	2.2	17
143	A Disintegrin and Metalloprotease-17 Regulates Pressure Overloadâ€“Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin Î²1. Hypertension, 2016, 68, 937-948.	2.7	37
144	Glycogen Storage Disease Because of a PRKAG2 Mutation Causing Severe Biventricular Hypertrophy and High-Grade Atrio-Ventricular Block. Circulation: Heart Failure, 2016, 9, .	3.9	12

#	Article	IF	Citations
145	The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides. ChemBioChem, 2016, 17, 1495-1498.	2.6	57
146	Ascending aortic adventitial remodeling and fibrosis are ameliorated with Apelin-13 in rats after TAC via suppression of the miRNA-122 and LGR4-Î²-catenin signaling. Peptides, 2016, 86, 85-94.	2.4	34
147	Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17. Hypertension, 2016, 68, 365-377.	2.7	152
148	Regulators of G-Protein Signaling 10 and Heart Failure. Hypertension, 2016, 67, 38-40.	2.7	2
149	ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity. Adipocyte, 2016, 5, 306-311.	2.8	90
150	Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure. Translational Research, 2016, 172, 30-44.	5.0	39
151	MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis. Heart Failure Reviews, 2016, 21, 103-116.	3.9	50
152	Amlodipine Therapy for Iron-Overload Cardiomyopathy: The Enduring Value of Translational Research. Canadian Journal of Cardiology, 2016, 32, 938-940.	1.7	6
153	Reduced Right Ventricular Native Myocardial T1 in Anderson-Fabry Disease: Comparison to Pulmonary Hypertension and Healthy Controls. PLoS ONE, 2016, 11, e0157565.	2.5	30
154	Increased Mortality Associated With Adaptive Servo-Ventilation Therapy in Heart Failure Patients WithÂCentral Sleep Apnea in the Halted SERVE-HF Trial. Canadian Journal of Cardiology, 2015, 31, 1202-1203.	1.7	6
155	Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy. Scientific Reports, 2015, 5, 18132.	3.3	85
156	Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling. Journal of Translational Medicine, 2015, 13, 255.	4.4	33
157	Determinants of ventricular arrhythmias in human explanted hearts with dilated cardiomyopathy. European Journal of Clinical Investigation, 2015, 45, 1286-1296.	3.4	31
158	Resveratrol Treatment of Mice With Pressure-Overloadâ€“Induced Heart Failure Improves Diastolic Function and Cardiac Energy Metabolism. Circulation: Heart Failure, 2015, 8, 128-137.	3.9	79
159	Genderâ€specific plasma proteomic biomarkers in patients with Andersonâ€“Fabry disease. European Journal of Heart Failure, 2015, 17, 291-300.	7.1	38
160	PI3KÎ± is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart. Cardiovascular Research, 2015, 105, 292-303.	3.8	16
161	Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Postâ€“Myocardial Infarction Repair by Regulating Angiogenesis. Circulation: Heart Failure, 2015, 8, 970-979.	3.9	38
162	Characterization of the Intrarenal Renin-Angiotensin System in Experimental Alport Syndrome. American Journal of Pathology, 2015, 185, 1423-1435.	3.8	27

#	Article	IF	Citations
163	Antagonism of angiotensin 1â€“7 prevents the therapeutic effects of recombinant human ACE2. Journal of Molecular Medicine, 2015, 93, 1003-1013.	3.9	38
164	Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Andersonâ€“Fabry disease. European Heart Journal Cardiovascular Imaging, 2015, 16, 1129-1136.	1.2	9
165	Letter by McLean and Oudit Regarding Article, â€œMyostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failureâ€. Circulation Research, 2015, 116, e51-2.	4.5	2
166	GW26-e3978 Regulatory roles of Angiotensin-Converting Enzyme 2 in NOX4 Expression and Oxidative Stress Levels in Kidneys of Apolipoprotein E-Deficient Mice. Journal of the American College of Cardiology, 2015, 66, C72-C73.	2.8	0
167	Quantification of circumferential, longitudinal, and radial global fractional shortening using steadyâ€state free precession cines: A comparison with tissueâ€tracking strain and application in fabry disease. Magnetic Resonance in Medicine, 2015, 73, 586-596.	3.0	12
168	Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment. Heart Failure Reviews, 2015, 20, 179-191.	3.9	58
169	Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. PLoS ONE, 2015, 10, e0124844.	2.5	150
170	The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure. , 2015, , 347-381.		0
171	Abstract 16611: Impact of Mechanical Unloading on Structural and Non-structural Components of the Extracellular Matrix in Patients With Dilated Cardiomyopathy. Circulation, 2015, 132, .	1.6	0
172	Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology. PLoS ONE, 2014, 9, e99495.	2.5	94
173	Dual loss of PI3KÎ± and PI3KÎ³ signaling leads to an age-dependent cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2014, 77, 155-159.	1.9	9
174	TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury. Kidney International, 2014, 85, 82-93.	5.2	52
175	Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clinical Science, 2014, 126, 471-482.	4.3	72
176	Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure. Clinical Science, 2014, 127, 331-340.	4.3	45
177	Proteomic biomarkers of recovered heart function. European Journal of Heart Failure, 2014, 16, 551-559.	7.1	12
178	Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment. Canadian Journal of Cardiology, 2014, 30, 1706-1715.	1.7	126
179	Cardiovascular Pathophysiology: Is It a Tumour Necrosis Factor Superfamily Affair?. Canadian Journal of Cardiology, 2014, 30, 1492-1495.	1.7	2
180	Novel Mutation in Exon 14 of the Sarcomere Gene MYH7 in Familial Left Ventricular Noncompaction With Bicuspid Aortic Valve. Circulation: Heart Failure, 2014, 7, 1059-1062.	3.9	27

#	Article	IF	Citations
181	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders, 2014, 14, 91.	1.7	27
182	Role of sex steroids and sexual dimorphism on cardiac iron metabolism in iron-overload cardiomyopathy. Translational Research, 2014, 163, 141-144.	5.0	3
183	Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. Journal of Molecular and Cellular Cardiology, 2014, 66, 167-176.	1.9	263
184	Angiotensin 1â€“7 Ameliorates Diabetic Cardiomyopathy and Diastolic Dysfunction in db/db Mice by Reducing Lipotoxicity and Inflammation. Circulation: Heart Failure, 2014, 7, 327-339.	3.9	158
185	Role of Autoimmunity in Heart Disease: Is Chagas Heart Disease the Definitive Proof?. Canadian Journal of Cardiology, 2014, 30, 267-269.	1.7	2
186	Angiotensin 1â€“7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. American Journal of Physiology - Renal Physiology, 2014, 306, F812-F821.	2.7	113
187	Angiotensin-Converting Enzyme 2 Is a Critical Determinant of Angiotensin Iiâ€“Induced Loss of Vascular Smooth Muscle Cells and Adverse Vascular Remodeling. Hypertension, 2014, 64, 157-164.	2.7	81
188	A Male-Specific mRNA Panel Improves Differentiation between Heart Failure with Reduced and Preserved Ejection Fraction. Journal of Cardiac Failure, 2014, 20, S28.	1.7	0
189	ACE2/Ang-(1â€“7) signaling and vascular remodeling. Science China Life Sciences, 2014, 57, 802-808.	4.9	44
190	Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. Journal of Molecular Medicine, 2014, 92, 847-858.	3.9	34
191	Gender-dependent aortic remodelling in patients with bicuspid aortic valve-associated thoracic aortic aneurysm. Journal of Molecular Medicine, 2014, 92, 939-949.	3.9	14
192	Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovascular Research, 2014, 103, 268-280.	3.8	98
193	Myocardial Recovery From Ischemiaâ€“Reperfusion Is Compromised in the Absence of Tissue Inhibitor of Metalloproteinase 4. Circulation: Heart Failure, 2014, 7, 652-662.	3.9	50
194	Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. Canadian Journal of Physiology and Pharmacology, 2014, 92, 558-565.	1.4	29
195	The Harbinger of Mortality in Heart Failure With Preserved Ejection Fraction: Do GDF-15 Levels Reflect Tandem, Deterministic Effects of Fibrosis and Inflammation?. Canadian Journal of Cardiology, 2014, 30, 264-266.	1.7	5
196	Phosphoinositide 3-kinase Î² mediates microvascular endothelial repair of thrombotic microangiopathy. Blood, 2014, 124, 2142-2149.	1.4	19
197	Abstract 18845: Left Ventricular Assist Device Normalizes Multiple Pathogenic Pathways in Both the Left and Right Ventricle in Patients With Dilated Cardiomyopathy. Circulation, 2014, 130, .	1.6	0
198	Impact of the reninâ€“angiotensin system on cardiac energy metabolism in heart failure. Journal of Molecular and Cellular Cardiology, 2013, 63, 98-106.	1.9	51

#	Article	IF	Citations
199	PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine. Journal of Cardiac Failure, 2013, 19, 268-282.	1.7	24
200	Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways. Regulatory Peptides, 2013, 185, 44-51.	1.9	50
201	Systolic and Diastolic Function Assessment in Fabry Disease Patients Using Speckle-Tracking Imaging and Comparison with Conventional Echocardiographic Measurements. Journal of the American Society of Echocardiography, 2013, 26, 1407-1414.	2.8	72
202	Enhanced recovery from ischemiaâ€“reperfusion injury in PI3KÎ± dominant negative hearts: Investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling. Journal of Molecular and Cellular Cardiology, 2013, 54, 9-18.	1.9	15
203	Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax, 2013, 68, 475-484.	5.6	217
204	Beneficial Effects of Grape Resveratrol on Serum Adiponectin and Inflammation: Clinical Trial in Patients with Stable Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2013, 27, 1-4.	2.6	4
205	A case of lamin A/C mutation cardiomyopathy with overlap features of ARVC: A critical role of genetic testing. International Journal of Cardiology, 2013, 168, 4325-4327.	1.7	20
206	Angiotensinâ€converting enzyme 2 antagonizes angiotensin IIâ€induced pressor response and NADPH oxidase activation in Wistarâ€“Kyoto rats and spontaneously hypertensive rats. Experimental Physiology, 2013, 98, 109-122.	2.0	56
207	S4153R Is a Gain-of-Function Mutation in the Cardiac Ca2+ Release Channel Ryanodine Receptor Associated With Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 993-996.	1.7	39
208	Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovascular Research, 2013, 97, 676-685.	3.8	112
209	The ACE2/Ang (1â€“7) Pathway in Cardiac Remodeling Due to Pressure Overload. , 2013, , 127-139.		0
210	T ₁ Mapping With Cardiovascular MRI Is Highly Sensitive for Fabry Disease Independent of Hypertrophy and Sex. Circulation: Cardiovascular Imaging, 2013, 6, 637-645.	2.6	158
211	ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 304, H1103-H1113.	3.2	138
212	Loss of p47 ^{phox} Subunit Enhances Susceptibility to Biomechanical Stress and Heart Failure Because of Dysregulation of Cortactin and Actin Filaments. Circulation Research, 2013, 112, 1542-1556.	4.5	51
213	Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemiaâ€reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues. Journal of the American Heart Association, 2013, 2, e000249.	3.7	171
214	GW24-e3625â€...Effects of apelin on the phosphodiesterase 1 expression and oxidative stress levels in mouse kidney fibroblast cells. Heart, 2013, 99, A11.2-A12.	2.9	0
215	Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. Journal of Translational Medicine, 2013, 11, 229.	4.4	32
216	Loss of Angiotensin-Converting Enzyme 2 Exacerbates Myocardial Injury via Activation of the CTGF-Fractalkine Signaling Pathway. Circulation Journal, 2013, 77, 2997-3006.	1.6	40

#	Article	IF	Citations
217	Loss of TIMP3 selectively exacerbates diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2012, 303, F1341-F1352.	2.7	39
218	Angiotensin-(1â€“7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. American Journal of Physiology - Renal Physiology, 2012, 302, F784-F790.	2.7	53
219	Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges. Cardiology Research and Practice, 2012, 2012, 1-11.	1.1	24
220	Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation. Circulation: Heart Failure, 2012, 5, 493-503.	3.9	136
221	Myocardial ATGL Overexpression Decreases the Reliance on Fatty Acid Oxidation and Protects against Pressure Overload-Induced Cardiac Dysfunction. Molecular and Cellular Biology, 2012, 32, 740-750.	2.3	95
222	Loss of Timp3 Gene Leads to Abdominal Aortic Aneurysm Formation in Response to Angiotensin II. Journal of Biological Chemistry, 2012, 287, 44083-44096.	3.4	62
223	ANGIOTENSIN II-MEDIATED MYOCARDIAL EXPRESSION OF MMP2, MMP9 AND MT1-MMP WERE ENHANCED IN ACE2-NULL MICE. Heart, 2012, 98, E9.2-E9.	2.9	0
224	Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e141-e148.	0.5	4
225	Cardioprotective Effects Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin 1-7 in Experimental Heart Failure in Angiotensin-Converting Enzyme 2â€“Null Mice. Hypertension, 2012, 59, 1195-1203.	2.7	97
226	Loss of Angiotensin-Converting Enzyme-2 Exacerbates Diabetic Cardiovascular Complications and Leads to Systolic and Vascular Dysfunction. Circulation Research, 2012, 110, 1322-1335.	4.5	141
227	Role of PI3KÎ± and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection. Journal of Molecular and Cellular Cardiology, 2012, 53, 43-52.	1.9	35
228	The Use of Ï‰-3 Poly-Unsaturated Fatty Acids in Heart Failure: A Preferential Role in Patients with Diabetes. Cardiovascular Drugs and Therapy, 2012, 26, 311-320.	2.6	20
229	Role of ACE2 in diastolic and systolic heart failure. Heart Failure Reviews, 2012, 17, 683-691.	3.9	63
230	Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews, 2012, 17, 597-613.	3.9	38
231	Voltageâ€gated <scp>C</scp>a²⁺ channels as key mediators of ironâ€transport and ironâ€overload cardiomyopathy: <scp>L</scp>â€type vs. <scp>T</scp>â€type <scp>C</scp>a⁺ channels. European Journal of Haematology, 2012, 88, 476-477.	2.2	10
232	ACE2 Deficiency Enhances Angiotensin II-Mediated Aortic Profilin-1 Expression, Inflammation and Peroxynitrite Production. PLoS ONE, 2012, 7, e38502.	2.5	73
233	Uncoupling between enhanced excitationâ€“contraction coupling and the response to heart disease: Lessons from the PI3KÎ³ knockout murine model. Journal of Molecular and Cellular Cardiology, 2011, 50, 606-612.	1.9	8
234	Prevention of Angiotensin IIâ€“Mediated Renal Oxidative Stress, Inflammation, and Fibrosis by Angiotensin-Converting Enzyme 2. Hypertension, 2011, 57, 314-322.	2.7	200

#	Article	IF	Citations
235	Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation. PLoS ONE, 2011, 6, e18273.	2.5	15
236	Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regulatory Peptides, 2011, 166, 90-97.	1.9	99
237	Use of ginseng to reduce post-myocardial adverse myocardial remodeling: applying scientific principles to the use of herbal therapies. Journal of Molecular Medicine, 2011, 89, 317-320.	3.9	7
238	Recombinant Human Angiotensin-Converting Enzyme 2 as a New Renin-Angiotensin System Peptidase for Heart Failure Therapy. Current Heart Failure Reports, 2011, 8, 176-183.	3.3	62
239	Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovascular Research, 2011, 91, 151-161.	3.8	76
240	Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting. European Journal of Heart Failure, 2011, 13, 1211-1215.	7.1	8
241	Lack of Tissue Inhibitor of Metalloproteinases 2 Leads to Exacerbated Left Ventricular Dysfunction and Adverse Extracellular Matrix Remodeling in Response to Biomechanical Stress. Circulation, 2011, 124, 2094-2105.	1.6	90
242	The Role of PI3K Isoforms and Sarcolemmal KATP Channel in Epoxyeicosatrienoic Acid Mediated Cardioprotection. FASEB Journal, 2011, 25, 1085.7.	0.5	0
243	Mice with Tissue Inhibitor of Metalloproteinases 4 (Timp4) Deletion Succumb to Induced Myocardial Infarction but Not to Cardiac Pressure Overload. Journal of Biological Chemistry, 2010, 285, 24487-24493.	3.4	80
244	Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction. Circulation, 2010, 122, 717-728.	1.6	383
245	Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy. Diabetes, 2010, 59, 529-538.	0.6	264
246	Role of Phosphoinositide 3-Kinase Î±, Protein Kinase C, and L-Type Ca ²⁺ Channels in Mediating the Complex Actions of Angiotensin II on Mouse Cardiac Contractility. Hypertension, 2010, 56, 422-429.	2.7	25
247	TIMP2 Deficiency Accelerates Adverse Postâ€“Myocardial Infarction Remodeling Because of Enhanced MT1-MMP Activity Despite Lack of MMP2 Activation. Circulation Research, 2010, 106, 796-808.	4.5	140
248	Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3KÎ³-dependent manner. American Journal of Physiology - Cell Physiology, 2010, 298, C679-C692.	4.6	98
249	Early activation of matrix metalloproteinases underlies the exacerbated systolic and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1012-H1023.	3.2	73
250	Loss of PI3KÎ³ Enhances cAMP-Dependent MMP Remodeling of the Myocardial N-Cadherin Adhesion Complexes and Extracellular Matrix in Response to Early Biomechanical Stress. Circulation Research, 2010, 107, 1275-1289.	4.5	50
251	Iron-Overload Cardiomyopathy: Pathophysiology, Diagnosis, and Treatment. Journal of Cardiac Failure, 2010, 16, 888-900.	1.7	218
252	Role of Signaling Pathways in the Myocardial Response to Biomechanical Stress and in Mechanotransduction in the Heart. , 2010, , 141-166.		1

#	Article	IF	Citations
253	Simultaneous Transforming Growth Factor Î²-Tumor Necrosis Factor Activation and Cross-talk Cause Aberrant Remodeling Response and Myocardial Fibrosis in Timp3-deficient Heart. Journal of Biological Chemistry, 2009, 284, 29893-29904.	3.4	82
254	The role of ACE2 in pulmonary diseases--relevance for the nephrologist. Nephrology Dialysis Transplantation, 2009, 24, 1362-1365.	0.7	26
255	Type 1 diabetic cardiomyopathy in the Akita (Ins2^{WT/C96Y}) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H2096-H2108.	3.2	139
256	Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction. Circulation: Heart Failure, 2009, 2, 446-455.	3.9	194
257	Loss of TIMP3 Enhances Interstitial Nephritis and Fibrosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 1223-1235.	6.1	112
258	Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology, 2009, 50, 929-938.	7.3	117
259	SARSâ€coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. European Journal of Clinical Investigation, 2009, 39, 618-625.	3.4	732
260	Acute coronary thrombosis in a patient with diabetes and severe hyperglycemia. Canadian Journal of Cardiology, 2009, 25, e217-e219.	1.7	2
261	Effects of parenteral iron on inflammation and the myocardium in hemodialysis patients. Hemodialysis International, 2008, 12, 362-368.	0.9	5
262	A case of appropriate inappropriate device therapy: Hyperkalemia-induced ventricular oversensing. Canadian Journal of Cardiology, 2008, 24, e16-e18.	1.7	7
263	Comparative Proteomics Profiling of a Phospholamban Mutant Mouse Model of Dilated Cardiomyopathy Reveals Progressive Intracellular Stress Responses. Molecular and Cellular Proteomics, 2008, 7, 519-533.	3.8	91
264	Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H1377-H1384.	3.2	267
265	Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. Cardiovascular Research, 2008, 78, 505-514.	3.8	107
266	Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R1675-R1683.	1.8	255
267	Phosphatidylinositol 3-Kinase Î³ Is a Critical Mediator of Myocardial Ischemic and Adenosine-Mediated Preconditioning. Circulation Research, 2008, 103, 643-653.	4.5	64
268	Erythropoietin Protects against Doxorubicin-Induced Cardiomyopathy via a Phosphatidylinositol 3-Kinase-Dependent Pathway. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 160-169.	2.5	102
269	Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney International, 2008, 74, 1610-1616.	5.2	209
270	Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovascular Research, 2008, 82, 250-260.	3.8	218

#	Article	IF	Citations
271	Left Ventricular Aneurysm Associated With Mucopolysaccharidosis Type VI Syndrome (Maroteauxâ€“Lamy Syndrome). Circulation, 2007, 115, e60-2.	1.6	8
272	Left ventricular aneurysm in a patient with mucopolysaccharidosis type VI (Maroteauxâ€“Lamy) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70	1.6	18
273	Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. American Journal of Pathology, 2007, 171, 438-451.	3.8	235
274	Lithium-induced sinus node disease at therapeutic concentrations: Linking lithium-induced blockade of sodium channels to impaired pacemaker activity. Canadian Journal of Cardiology, 2007, 23, 229-232.	1.7	41
275	Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovascular Research, 2007, 75, 29-39.	3.8	215
276	Role of PI3 Kinase Gamma in Excitation-Contraction Coupling and Heart Disease. Cardiovascular & Hematological Disorders Drug Targets, 2007, 7, 295-304.	0.7	17
277	Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis. American Journal of Pathology, 2006, 168, 1808-1820.	3.8	214
278	Calcific bicuspid aortic valve disease in a patient with Cornelia de Lange syndrome: linking altered Notch signaling to aortic valve disease. Cardiovascular Pathology, 2006, 15, 165-167.	1.6	4
279	Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. Journal of Molecular Medicine, 2006, 84, 349-364.	3.9	176
280	Insulin-Like Growth Factor-1 and PTEN Deletion Enhance Cardiac L-Type Ca 2+ Currents via Increased PI3KÎ±/PKB Signaling. Circulation Research, 2006, 98, 1390-1397.	4.5	67
281	Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6043-6048.	7.1	93
282	Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2446-2451.	7.1	75
283	Cardiac Sarcoplasmic Reticulum Calcium Release and Load Are Enhanced by Subcellular cAMP Elevations in PI3KÎ³-Deficient Mice. Circulation Research, 2005, 96, 1079-1086.	4.5	30
284	Muscle-Specific Loss of Apoptosis-Inducing Factor Leads to Mitochondrial Dysfunction, Skeletal Muscle Atrophy, and Dilated Cardiomyopathy. Molecular and Cellular Biology, 2005, 25, 10261-10272.	2.3	208
285	Distinct functions of junD in cardiac hypertrophy and heart failure. Genes and Development, 2005, 19, 208-213.	5.9	44
286	Combination of Tumor Necrosis Factor-Î± Ablation and Matrix Metalloproteinase Inhibition Prevents Heart Failure After Pressure Overload in Tissue Inhibitor of Metalloproteinase-3 Knock-Out Mice. Circulation Research, 2005, 97, 380-390.	4.5	151
287	Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9199-9204.	7.1	99
288	The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik,slow currents. Cardiovascular Research, 2004, 62, 509-520.	3.8	31

#	Article	IF	Citations
289	The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. Journal of Molecular and Cellular Cardiology, 2004, 37, 449-471.	1.9	413
290	Taurine Supplementation Reduces Oxidative Stress and Improves Cardiovascular Function in an Iron-Overload Murine Model. Circulation, 2004, 109, 1877-1885.	1.6	195
291	The Role of ACE2 in Cardiovascular Physiology. Trends in Cardiovascular Medicine, 2003, 13, 93-101.	4.9	232
292	Regulation of cardiac excitationâ€“contraction coupling by action potential repolarization: role of the transient outward potassium current (I to). Journal of Physiology, 2003, 546, 5-18.	2.9	228
293	L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nature Medicine, 2003, 9, 1187-1194.	30.7	402
294	Dendritic cellâ€“induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nature Medicine, 2003, 9, 1484-1490.	30.7	404
295	Sulfhydryl modulation of K+ currents: a possible cross-link between oxidative stress and altered cardiovascular function. Journal of Molecular and Cellular Cardiology, 2003, 35, 1-4.	1.9	3
296	Phosphoinositide 3-Kinase Î³â€“Deficient Mice Are Protected From Isoproterenol-Induced Heart Failure. Circulation, 2003, 108, 2147-2152.	1.6	155
297	Electrophysiological Profiling of Cardiomyocytes in Embryonic Bodies Derived From Human Embryonic Stem Cells. Circulation Research, 2003, 93, 1-3.	4.5	15
298	Inhibition of Calcineurin and Sarcolemmal Ca 2+ Influx Protects Cardiac Morphology and Ventricular Function in K v 4.2N Transgenic Mice. Circulation, 2002, 105, 1850-1856.	1.6	58
299	Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways. Cell, 2002, 110, 737-749.	28.9	545
300	Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 2002, 417, 822-828.	27.8	1,586
301	The Molecular Physiology of the Cardiac Transient Outward Potassium Current (Ito) in Normal and Diseased Myocardium. Journal of Molecular and Cellular Cardiology, 2001, 33, 851-872.	1.9	175
302	Modulation of Iron Uptake in Heart by L-Type Ca ²⁺ Channel Modifiers. Circulation Research, 1999, 84, 1302-1309.	4.5	146
303	Angiotensin-I- and -III-Mediated Cardiovascular Responses in the Freshwater North American Eel, Anguilla rostrata: Effect of Phe8 Deletion. General and Comparative Endocrinology, 1995, 97, 259-269.	1.8	19
304	Angiotensin I- and II- and Norepinephrine-Mediated Pressor Responses in an Ancient Holostean Fish, the Bowfin (Amia calva). General and Comparative Endocrinology, 1995, 98, 289-302.	1.8	11